Many Americans now are fully vaccinated. But that doesn't mean the opportunity is over for latecomers to the coronavirus vaccine market. In this Motley Fool Live video recorded on June 22, healthcare and cannabis bureau editor and analyst Olivia Zitkus and Fool.com contributor Adria Cimino discuss Novavax's (NVAX 3.55%) vaccine orders -- and where Novavax may carve out market share.
Olivia Zitkus: As of yesterday, I think it was over 45% of Americans at least are fully vaccinated. That's not quite the picture in other countries, but in America, 45% are fully vaccinated. Geographically, where is Novavax's opportunity? It's got some deals in place already, a good amount of deals. But is there still opportunity in the U.S. or where is it looking to sell its vaccines?
Adria Cimino: Well, as you mentioned, they already have some deals. They have 200 million doses plus 1 billion through Covax -- and that's all about equity in vaccines. The idea is they're sold to lower to middle income countries. Of course the vaccine sold to Covax are going to be sold at a lower price, but still that is a lot of vaccine. They have a lot of doses out there. The U.S. opportunity is more long-term, because they already have a deal with the U.S., but I would say that in the future it's more like next year or the following year. One big thing to watch right now is they're in discussions with the European Commission for the European Union for a deal on doses there. They're in talks right now, nothing is decided yet, but that's something to keep an eye on because that could be a pretty big deal for Novavax.
Zitkus: Great. Even if the U.S. is all booked up, so to speak, for 2021, that future opportunity can still pay off in the long run?
Cimino: Right. Absolutely.
